Oncolytics Biotech (ONCY) Competitors

Oncolytics Biotech (NASDAQ:ONCY) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, community ranking, earnings, analyst recommendations, dividends and valuation.

Which has more risk and volatility, ONCY or ENLV?

Oncolytics Biotech has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.

Do institutionals and insiders believe in ONCY or ENLV?

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has higher valuation & earnings, ONCY or ENLV?

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$20.56M	-$0.27	-3.63
Enlivex Therapeutics	N/A	N/A	-$29.07M	-$1.18	-0.91

Does the media refer more to ONCY or ENLV?

In the previous week, Oncolytics Biotech had 11 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 17 mentions for Oncolytics Biotech and 6 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.28 beat Oncolytics Biotech's score of 0.02 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncolytics Biotech	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enlivex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate ONCY or ENLV?

Oncolytics Biotech presently has a consensus price target of $4.00, suggesting a potential upside of 308.16%. Enlivex Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 460.75%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Oncolytics Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Enlivex Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Does the MarketBeat Community prefer ONCY or ENLV?

Oncolytics Biotech received 103 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 79.10% of users gave Enlivex Therapeutics an outperform vote while only 68.12% of users gave Oncolytics Biotech an outperform vote.

Company	Underperform	Outperform
Oncolytics Biotech	Outperform Votes 156 68.12%	Underperform Votes 73 31.88%
Enlivex Therapeutics	Outperform Votes 53 79.10%	Underperform Votes 14 20.90%

Is ONCY or ENLV more profitable?

Enlivex Therapeutics' return on equity of -71.76% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-141.15%	-84.73%
Enlivex Therapeutics	N/A	-71.76%	-60.78%

Summary

Enlivex Therapeutics beats Oncolytics Biotech on 9 of the 16 factors compared between the two stocks.